Therapeutic strategies for Parkinson’s disease: promising agents in early clinical development
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic strategies for Parkinson’s disease: promising agents in early clinical development
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-19
Publisher
Informa UK Limited
Online
2020-08-28
DOI
10.1080/13543784.2020.1814252
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Beta 2 agonists and the incidence of Parkinson’s disease
- (2020) Francesco Giorgianni et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Glucocerebrosidase as a therapeutic target for Parkinson’s disease
- (2020) Yu Chen et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- LRRK2 in Parkinson disease: challenges of clinical trials
- (2020) Eduardo Tolosa et al. Nature Reviews Neurology
- Genetic causes of PD: A pathway to disease modification
- (2020) M. Toffoli et al. NEUROPHARMACOLOGY
- Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts
- (2020) Margaux Teil et al. Biomolecules
- Therapeutic potential of stem cells for treatment of neurodegenerative diseases
- (2020) Hamid Ahmadian-Moghadam et al. BIOTECHNOLOGY LETTERS
- Immunization therapies for Parkinson’s disease: state of the art and considerations for future clinical trials
- (2020) Angelo Antonini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Gene therapy for Parkinson’s disease: contemporary practice and emerging concepts
- (2020) Aristide Merola et al. Expert Review of Neurotherapeutics
- Genetics of Parkinson's disease: An introspection of its journey towards precision medicine
- (2020) Sara Bandres-Ciga et al. NEUROBIOLOGY OF DISEASE
- The effect of mutant GBA1 on accumulation and aggregation of α-synuclein
- (2019) Gali Maor et al. HUMAN MOLECULAR GENETICS
- Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases
- (2019) Alberto J. Espay et al. NEUROLOGY
- Emerging therapies in Parkinson disease — repurposed drugs and new approaches
- (2019) Ahmad Elkouzi et al. Nature Reviews Neurology
- Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial
- (2019) Peter A LeWitt et al. LANCET NEUROLOGY
- Extended-Release Amantadine for Levodopa-Induced Dyskinesia
- (2019) Khashayar Dashtipour et al. Expert Review of Neurotherapeutics
- Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson's disease
- (2019) Peter A. LeWitt et al. PARKINSONISM & RELATED DISORDERS
- Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations
- (2019) Nishit B. Modi et al. CLINICAL NEUROPHARMACOLOGY
- Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054
- (2019) Miroslaw Brys et al. MOVEMENT DISORDERS
- Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study
- (2019) C Warren Olanow et al. LANCET NEUROLOGY
- Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study
- (2019) Tanya Simuni et al. LANCET NEUROLOGY
- Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study
- (2019) Donald G. Grosset et al. PARKINSONISM & RELATED DISORDERS
- Managing Gait, Balance, and Posture in Parkinson’s Disease
- (2018) Bettina Debû et al. Current Neurology and Neuroscience Reports
- Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia
- (2018) Santiago Perez-Lloret et al. JOURNAL OF NEURAL TRANSMISSION
- The accuracy of the clinical diagnosis of Parkinson disease. The HUNT study
- (2018) Eldbjørg Hustad et al. JOURNAL OF NEUROLOGY
- Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
- (2018) S. Pablo Sardi et al. MOVEMENT DISORDERS
- Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
- (2018) Anthony E. Lang et al. MOVEMENT DISORDERS
- The Parkinson Pandemic—A Call to Action
- (2018) E. Ray Dorsey et al. JAMA Neurology
- Mitochondrial Dysfunction and Mitophagy Defect Triggered by Heterozygous GBA Mutations
- (2018) Hongyu Li et al. Autophagy
- Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies
- (2018) Xiaoguang Liu et al. HUMAN MOLECULAR GENETICS
- Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
- (2018) Delphine Charvin et al. NATURE REVIEWS DRUG DISCOVERY
- L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey
- (2017) S. Perez-Lloret et al. EUROPEAN JOURNAL OF NEUROLOGY
- Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress
- (2017) Lisa D. Coles et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Targeting α-Synuclein as a therapy for Parkinson's disease: The battle begins
- (2017) C. Warren Olanow et al. MOVEMENT DISORDERS
- Personalized medicine in Parkinson's disease: Time to be precise
- (2017) Nataliya Titova et al. MOVEMENT DISORDERS
- Mucuna pruriens in Parkinson disease
- (2017) Roberto Cilia et al. NEUROLOGY
- Caffeine as symptomatic treatment for Parkinson disease (Café-PD)
- (2017) Ronald B. Postuma et al. NEUROLOGY
- Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease
- (2017) Laurie K. Mischley et al. Journal of Parkinsons Disease
- Glucocerebrosidase Mutations in Parkinson Disease
- (2017) Grace O’Regan et al. Journal of Parkinsons Disease
- Parkinson disease
- (2017) Werner Poewe et al. Nature Reviews Disease Primers
- Levodopa in Parkinson’s Disease: Current Status and Future Developments
- (2017) Nicola Tambasco et al. Current Neuropharmacology
- Multiple-Ascending-Dose Pharmacokinetics and Safety Evaluation of Baicalein Chewable Tablets in Healthy Chinese Volunteers
- (2016) Hongxian Pang et al. CLINICAL DRUG INVESTIGATION
- Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease
- (2016) Joana Magalhaes et al. HUMAN MOLECULAR GENETICS
- A New Glucocerebrosidase Chaperone Reduces -Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism
- (2016) E. Aflaki et al. JOURNAL OF NEUROSCIENCE
- Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
- (2016) Joaquim J Ferreira et al. LANCET NEUROLOGY
- Mavoglurant in Parkinson's patients withl-Dopa-induced dyskinesias: Two randomized phase 2 studies
- (2016) Claudia Trenkwalder et al. MOVEMENT DISORDERS
- A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia
- (2016) Claudia Trenkwalder et al. MOVEMENT DISORDERS
- Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease
- (2016) Robert A. Hauser et al. MOVEMENT DISORDERS
- Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysisAuthor Response
- (2016) Kurt A. Jellinger et al. NEUROLOGY
- Non-motor symptoms in Parkinson's disease
- (2016) Ronald F. Pfeiffer PARKINSONISM & RELATED DISORDERS
- Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain
- (2016) Wen Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
- (2016) Fernando Pagan et al. Journal of Parkinsons Disease
- N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data
- (2016) Daniel A. Monti et al. PLoS One
- Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
- (2015) Guillaume Grolez et al. BMC Neurology
- Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
- (2015) Per Svenningsson et al. BRAIN
- Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease
- (2015) Karl Kieburtz et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
- (2015) LANCET NEUROLOGY
- A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease
- (2015) Laurie K. Mischley et al. MOVEMENT DISORDERS
- Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias
- (2015) Perdita Cheshire et al. MOVEMENT DISORDERS
- MDS research criteria for prodromal Parkinson's disease
- (2015) Daniela Berg et al. MOVEMENT DISORDERS
- Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease
- (2015) Asako Yoritaka et al. PARKINSONISM & RELATED DISORDERS
- Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease
- (2015) Robert A. Hauser et al. JAMA Neurology
- Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons
- (2014) Wei Shen et al. JOURNAL OF NEUROCHEMISTRY
- Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
- (2014) Robert A Hauser et al. LANCET NEUROLOGY
- Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial
- (2014) H. Kaufmann et al. NEUROLOGY
- AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys
- (2014) Thérèse Di Paolo et al. PARKINSONISM & RELATED DISORDERS
- Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease
- (2014) Michael A. Schwarzschild et al. JAMA Neurology
- A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
- (2014) et al. JAMA Neurology
- Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys
- (2013) Ariadna Recasens et al. ANNALS OF NEUROLOGY
- Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
- (2013) David Devos et al. ANTIOXIDANTS & REDOX SIGNALING
- New Pharmacological Options for Treating Advanced Parkinson’s Disease
- (2013) David Devos et al. CLINICAL THERAPEUTICS
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
- (2013) Jeffrey Cummings et al. LANCET
- Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
- (2013) Robert A Hauser et al. LANCET NEUROLOGY
- Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
- (2013) C Warren Olanow et al. LANCET NEUROLOGY
- Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
- (2013) Rupam Borgohain et al. MOVEMENT DISORDERS
- Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
- (2013) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)
- (2013) MOVEMENT DISORDERS
- Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder?
- (2013) C. Warren Olanow et al. MOVEMENT DISORDERS
- Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease
- (2012) Scott Ayton et al. ANNALS OF NEUROLOGY
- Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity
- (2012) C. Yao et al. HUMAN MOLECULAR GENETICS
- Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial
- (2012) Caroline Moreau et al. LANCET NEUROLOGY
- RETRACTED: Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson’s disease with combined noradrenergic and serotonergic lesions
- (2012) N. Rampersaud et al. NEUROPEPTIDES
- Glutathione synthesis and its role in redox signaling
- (2012) Hongqiao Zhang et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons
- (2011) Christina E. Khodr et al. BRAIN RESEARCH
- Treatment of Dementia with Lewy Bodies and Parkinsonʼs Disease Dementia
- (2011) Clive Ballard et al. DRUGS & AGING
- Ceruloplasmin Oxidation, a Feature of Parkinson's Disease CSF, Inhibits Ferroxidase Activity and Promotes Cellular Iron Retention
- (2011) S. Olivieri et al. JOURNAL OF NEUROSCIENCE
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
- (2011) Olivier Rascol et al. LANCET NEUROLOGY
- Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
- (2011) Kurt A. Jellinger MOVEMENT DISORDERS
- The Parkinson Progression Marker Initiative (PPMI)
- (2011) Kenneth Marek et al. PROGRESS IN NEUROBIOLOGY
- N-acetylcysteine prevents loss of dopaminergic neurons in theEAAC1−/−mouse
- (2010) Ari E. Berman et al. ANNALS OF NEUROLOGY
- In Vivo RNAi-Mediated α-Synuclein Silencing Induces Nigrostriatal Degeneration
- (2010) Oleg S Gorbatyuk et al. MOLECULAR THERAPY
- Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease
- (2010) K. A. Chung et al. NEUROLOGY
- Oral N-Acetyl-Cysteine Attenuates Loss of Dopaminergic Terminals in α-Synuclein Overexpressing Mice
- (2010) Joanne Clark et al. PLoS One
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
- (2009) C. Warren Olanow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease
- (2008) Robert A. Hauser et al. MOVEMENT DISORDERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started